These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial. Watanabe H; Domei T; Morimoto T; Natsuaki M; Shiomi H; Toyota T; Ohya M; Suwa S; Takagi K; Nanasato M; Hata Y; Yagi M; Suematsu N; Yokomatsu T; Takamisawa I; Doi M; Noda T; Okayama H; Seino Y; Tada T; Sakamoto H; Hibi K; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Hanaoka KI; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T; Cardiovasc Interv Ther; 2021 Jan; 36(1):91-103. PubMed ID: 32086787 [TBL] [Abstract][Full Text] [Related]
9. Clinical impact of dual antiplatelet therapy use in patients following everolimus-eluting stent implantation: insights from the SEEDS study. Zhang YJ; Zhao YL; Xu B; Han YL; Li B; Liu Q; Su X; Pang S; Lu SZ; Guo XF; Yang YJ Chin Med J (Engl); 2015 Mar; 128(6):714-20. PubMed ID: 25758261 [TBL] [Abstract][Full Text] [Related]
10. Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials. Généreux P; Rutledge DR; Palmerini T; Caixeta A; Kedhi E; Hermiller JB; Wang J; Krucoff MW; Jones-McMeans J; Sudhir K; Simonton CA; Serruys PW; Stone GW Circ Cardiovasc Interv; 2015 May; 8(5):. PubMed ID: 25940520 [TBL] [Abstract][Full Text] [Related]
11. 6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation: The IVUS-XPL Randomized Clinical Trial. Hong SJ; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Her AY; Kim YH; Jang Y; Hong MK; JACC Cardiovasc Interv; 2016 Jul; 9(14):1438-46. PubMed ID: 27212028 [TBL] [Abstract][Full Text] [Related]
12. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. Colombo A; Chieffo A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Oteo Dominguez JF; Steffanon L; Tarantini G; Presbitero P; Menozzi A; Pucci E; Mauri J; Cesana BM; Giustino G; Sardella G J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2086-97. PubMed ID: 25236346 [TBL] [Abstract][Full Text] [Related]
13. Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 Trial. Yamamoto K; Watanabe H; Morimoto T; Domei T; Ohya M; Ogita M; Takagi K; Suzuki H; Nikaido A; Ishii M; Fujii S; Natsuaki M; Yasuda S; Kaneko T; Tamura T; Tamura T; Abe M; Kawai K; Nakao K; Ando K; Tanabe K; Ikari Y; Igarashi Hanaoka K; Morino Y; Kozuma K; Kadota K; Furukawa Y; Nakagawa Y; Kimura T; Circ Cardiovasc Interv; 2021 May; 14(5):e010384. PubMed ID: 34003662 [TBL] [Abstract][Full Text] [Related]
14. Two-year clinical outcomes of the NOBORI biolimus-eluting stents versus XIENCE/PROMUS everolimus-eluting stents in small vessel disease. Jinnouchi H; Kuramitsu S; Shinozaki T; Hiromasa T; Kobayashi Y; Morinaga T; Yamaji K; Soga Y; Shirai S; Ando K Catheter Cardiovasc Interv; 2016 Nov; 88(5):E132-E138. PubMed ID: 26708085 [TBL] [Abstract][Full Text] [Related]
15. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY). Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G; JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420 [TBL] [Abstract][Full Text] [Related]
16. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial. Sabaté M; Brugaletta S; Cequier A; Iñiguez A; Serra A; Hernádez-Antolín R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vázquez N; Backx B; Serruys PW JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423 [TBL] [Abstract][Full Text] [Related]
17. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL; Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy outcomes of second-generation everolimus-eluting stents in octogenarians compared to non-octogenarians. Kitabata H; Kubo T; Mori K; Yamamoto Y; Kashiwagi M; Arita Y; Tanimoto T; Akasaka T Cardiovasc Revasc Med; 2018 Jan; 19(1 Pt A):12-16. PubMed ID: 28600019 [TBL] [Abstract][Full Text] [Related]
19. Impact of total stent length after cobalt chromium everolimus-eluting stent implantation on 3-year clinical outcomes. Hiromasa T; Kuramitsu S; Shinozaki T; Jinnouchi H; Morinaga T; Kobayashi Y; Domei T; Soga Y; Shirai S; Ando K Catheter Cardiovasc Interv; 2017 Feb; 89(2):207-216. PubMed ID: 26910036 [TBL] [Abstract][Full Text] [Related]